Lidocaine Hydrochloride is named as a drug or biological intervention in 2 clinical trials in our USA and China trial registers, none of which are currently recruiting. Lead sponsors include Harrow Inc (1) and West China Hospital (1). Registered phases: Phase 4 and Not applicable. Conditions studied include Diabetic Macular Edema (DME); Age-Related Macular Degeneration (AMD); Retinal Vein Occlusion.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07783867 | The Effect of Perioperative Intravenous Lidocaine Infusion on Post-amputation Pain in Amputee Patients (ClinicalTrials.gov ↗) Amputation |
Not applicable | Not yet open |
| NCT07456826 | Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections (ClinicalTrials.gov ↗) Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion |
Phase 4 | By invitation |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Diabetic Macular Edema (DME) | 1 |
| Age-Related Macular Degeneration (AMD) | 1 |
| Retinal Vein Occlusion | 1 |
| Diabetic Retinopathy (DR) | 1 |
| Amputation | 1 |
| Lead sponsor | Trials |
|---|---|
| Harrow Inc | 1 |
| West China Hospital | 1 |
| Register | Lidocaine Hydrochloride trials |
|---|---|
| Clinical trials in USA | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lidocaine Hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lidocaine Hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.